30 results
424B4
CYCN
Cyclerion Therapeutics Inc
24 Jun 21
Prospectus supplement with pricing info
10:33am
Corrupt Practices Act (the “FCPA”) and other worldwide anti-bribery laws.
Risks Related to the Separation
Our rights under the intellectual property … Practices Act and other worldwide anti-bribery laws.
We are subject to the FCPA, which prohibits U.S. corporations and their representatives from offering
424B5
dm7hojckz
3 Sep 20
Prospectus supplement for primary offering
4:54pm
8-K
EX-10.1
fi0 dg3af2t8uc
3 Sep 20
Entry into a Material Definitive Agreement
6:30am
424B4
zn953zgc
17 Aug 20
Prospectus supplement with pricing info
1:07pm
S-3
eytjswsdw5 ekt8z
24 Jul 20
Shelf registration
5:13pm
10-K
ky00 ruu47
12 Mar 20
Annual report
4:58pm
424B3
dyzcrgbj
23 Apr 19
Prospectus supplement
5:12pm
S-1
0ktsswz9
18 Apr 19
IPO registration
5:04pm
DRS
cswxodz3aljjso qr
9 Apr 19
Draft registration statement
12:00am
8-K
EX-10.5
5cqs2p7x
2 Apr 19
Entry into a Material Definitive Agreement
5:05pm
8-K
EX-99.1
ekcuojvh0kx85 l7
2 Apr 19
Entry into a Material Definitive Agreement
5:05pm